Marker Therapeutics Inc.
Houston, TX Marker Therapeutics, Inc.
- UEI
- CK3KR85CSP23
- CAGE
- 6S1V6
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2450 Holcombe Blvd, Houston, TX 77021, USA
- Website
- markertherapeutics.com
- Founded
- 2018
- Employees
- 51-250
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Grant, phase 2 trial of patient-derived multitumor-associated antigen-specific t cells (MT-601) to treat… | Defense Health Agency | $4,170,167 | |
| A phase 1 study of patient-derived multi-tumor associated antigen specific t cells (MT-601) administered to patients… | National Cancer Institute | $1,348,550 | |
| A phase 1 study of patient-derived multi-tumor-associated antigen specific t cells (MT-601) administered to patients… | National Cancer Institute | $1,995,000 | |
| Controlling tumor immune escape in pancreatic cancer using a dual t cell product strategy - abstract while t cell… | National Cancer Institute | $3,300,487 | |
| Phase 2 clinical trial of a novel t cell therapy following bridging therapy with hypomethylating agents for relapsed AML… | National Cancer Institute | $2,659,352 |
About Marker Therapeutics Inc.
Marker Therapeutics Inc. is a biotechnology company focused on developing innovative T-cell immunotherapies for treating various types of cancer. As a self-certified small disadvantaged business and for-profit organization, the company specializes in developing multi-tumor associated antigen (MTAA)-specific T-cell therapies that target multiple cancer-associated antigens simultaneously. The company's research and development efforts are primarily directed at creating cellular immunotherapies designed to overcome traditional limitations in cancer treatment, with a particular emphasis on developing therapies for challenging cancer indications such as pancreatic cancer, non-Hodgkin lymphoma, and acute myeloid leukemia.
Through its federal grant awards, primarily from the National Cancer Institute, Marker Therapeutics has been developing and conducting clinical research on several novel T-cell therapy products, including MT-601 for pancreatic cancer and non-Hodgkin lymphoma, and MT-401 for acute myeloid leukemia. The company's grant-funded projects focus on advancing innovative therapeutic strategies, such as a binary T-cell approach that aims to transform the immunosuppressive tumor microenvironment and enhance anti-tumor immune responses. These projects involve Phase 1 and Phase 2 clinical trials investigating the safety, efficacy, and potential of their multi-tumor associated antigen-specific T-cell therapies in patients who have relapsed after standard treatments or who have limited therapeutic options. The grants, ranging from approximately $650,000 to $675,000, support research that seeks to provide proof-of-concept data to support future clinical trials and potential regulatory approval of these advanced immunotherapeutic products.
Quick answers
What is Marker Therapeutics Inc.'s UEI?
Marker Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is CK3KR85CSP23.
What is Marker Therapeutics Inc.'s CAGE code?
Marker Therapeutics Inc.'s CAGE code is 6S1V6.
What is Marker Therapeutics Inc.'s primary NAICS code?
Marker Therapeutics Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Marker Therapeutics Inc. located?
Marker Therapeutics Inc.'s physical address in SAM.gov is 2450 Holcombe Blvd, Houston, TX 77021, USA.
Is Marker Therapeutics Inc. registered in SAM.gov?
Yes. Marker Therapeutics Inc.'s SAM.gov registration is active through September 17, 2027.
What is Marker Therapeutics Inc.'s most recent federal award?
Marker Therapeutics Inc.'s most recent federal grant award is Grant, phase 2 trial of patient-derived multitumor-associated antigen-specific t cells (MT-601) to treat… (HT9425261E440), from Defense Health Agency, on August 15, 2026.
On GovTribe
See Marker Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors